ArticleFrontiers in cardiovascular medicine2021

Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region.

Chia-Te Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.